Transgenic mouse models for gonadal tumorigenesis

Molecular and Cellular Endocrinology

Volumn 145, Issue 1-2, 1998, Pages 167-174

  Rahman, Nafis A ^a   Kananen Rilianawati, Kirsi ^a   Paukku, Tommi ^a   Mikola, Maarit ^a   Markkula, Merja ^a   Hämäläinen, Tuula ^a   Huhtaniemi, Ilpo T ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

Gene therapy; Targeted gonadal tumorigenesis; Transgenic mice

Indexed keywords

ANIMAL MODEL; CONFERENCE PAPER; GENE THERAPY; GONAD TUMOR; MOUSE; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; THECOMA; TISSUE SPECIFICITY; TRANSGENIC MOUSE; VIRUS CARCINOGENESIS;

EID: 0032566938     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(98)00184-1     Document Type: Conference Paper

References (70)

1. Alarid E.T., Windle J.J., Whyte D.B., Mellon P.L. Immortalization of pituitary cells at discrete stages of development by oncogenesis in transgenic mice. Development. 122:1996;3319-3329.
2. Amsterdam A., Rotmensch S. Structure-function relationships during granulosa cell differentiation. Endocr. Rev. 8:1987;309-337.
3. Ascoli M. Characterization of several clonal cell lines of cultured Leydig tumor cells: gonadotropin receptors and steroidogenic response. Endocrinology. 108:1981;88-95.
4. Bautch V.L. Effects of polyoma virus oncogenes in trangenic mice. Mol. Biol. Med. 6:1989;309-317.
5. Beck C., Cayeux S., Lupton S.D., Dörken R., Blankenstein T. The thymidine kinase/gancyclovir-mediated suicide effect is variable in different tumor cells. Hum. Gene Ther. 6:1995;1525-1530.
6. Behringer R.R., Cate R.L., Froelick G.J., Palmiter R.D., Brinster R.L. Abnormal sexual development in transgenic mice chronically expressing Müllerian inhibiting substance. Nature. 345:1990;167-170.
7. Bhasin S., Krummen L.A., Swerdloff R.S. Stage dependent expression of inhibin alpha and beta-B subunits during the cycle of the rat semineferous epithelium. Endocrinology. 124:1989;987-991.
8. v genotype. Biol. Reprod. 53:1995;775-779.
9. Briers T.W., van der Voorde A., Vanderstichele H. Characterization of immortalized mouse granulosa cells. In Vitro Cell Dev. Biol. 29:1993;847-854.
10. Brinster R.L., Chen H.Y., Messing A., Dyke T., Levine A.J., Palmiter R.D. Transgenic mice harboring SV 40 T-antigen genes develop characteristic brain tumors. Cell. 37:1984;367-379.
11. Camper S.A., Saunders T.I., Kendall S.K., Keri R.A., Seasholtz A.F., Gordon D.F., Birkmeier T.S., Keegan C.E., Karolyi J., Roller M.I., Burrows H.I., Samuelson L.C. Implementing transgenic and embryonic stem cell technology to study gene expression, cell-cell interactions and gene-function. Biol. Reprod. 52:1995;246-257.
12. Camper S.A., Saunders T.I., Kendall S.K., Keri R.A., Seaholtz A.F., Gordon D.F., Birkmeier T.S., Keegan C.E., Karolyi I.J., Roller M.I., Burrows H.I., Samuelson L.C. Implementing transgenic and embryonic stem cell technology to study gene expression, cell-cell interactions and gene function. Biol. Reprod. 52:1995;246-257.
13. Camper S.A. Research applications of transgenic mice. Biotechniques. 5:1987;638-650.
14. Cattanach B.M., Iddon C.A., Charlton H.M., Chiappa S.A., Fink G. Gonadotrophin-releasing hormone deficiency in a mutant mouse with hypogonadism. Nature. 269:1977;338-340.
15. Chafiour L.E., Mes-Masson A.-M., Gomes M.L., Wang N.-S. Testicular adenoma and seminal vesicle engorgement in polyomavirus large T-antigen transgenic mice. Molec. Carcinog. 5:1992;178-189.
16. Cramer D.W., Welch W.R. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J. Natl.Cancer Inst. 71:1983;717-721.
17. de Kretser D.M., McFarlane J.R. Inhibin in the male. J. Androl. 17:1996;179-182.
18. Dilworth S.M. Cell alterations induced by large T-antigens of SV 40 and polyoma virus. Semin. Cancer Biol. 1:1990;407-414.
19. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montogomery C.A., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature. 265:1992;215-221.
20. Elion G.B. The biochemistry and mechanism of action of acyclovir. J. Antimicob. Chemiother. 12:1983;9-12.
21. Elson A., Leder P. Protein-thyrosein phosphatase epsilon. An isoform specifically expressed in mouse mammary tumors initiated by v-Ha-ras or neu. J. Biol. Chem. 270:1995;26116-26122.
22. Garde S.V., Sheth A.R. Immunoperoxidase localization of prostatic inhibin peptide in human, monkey, dog, and rat prostates. Anatom. Rec. 223:1989;181-184.
23. Gharib S.D., Wierman M. E., Shupnik M.A., Chin W.W. Molecular biology of the pituitary gonadotropins. Endocr. Rev. 11:1990;177-199.
24. Greenhalgh D.A., Wang X.J., Rothnagel J.A., Eckhardt J.N., Quintanilla M.I., Barber J.L., Bundman D.S., Longley M.A., Schlegel R., Roop D.R. Transgenic mice expressing targeted HPV-18 E6 and E7 oncogenes in the epidermis develop verrucous lesions and spontaneous, rasHa-activated papillomas. Cell Growth Different. 5:1994;667-675.
25. Hanahan D. Heritable formation of pancreatic β-cell tumors in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature. 315:1985;115-122.
26. Hanahan D. Transgenic mice as probes into complex systems. Science. 246:1989;1265-1275.
27. Hansen L.A., Trempus C.S., Mahler J.F., Tennant R.W. Association of tumor development with increased cellular proliferation and transgene overexpression, but not c-Ha-ras mutations, in v-Ha-ras transgenic Tg.AC mice. Carcinogenesis. 17:1996;1825-1833.
28. Hogan B., Beddington R., Constantini F., Lacy E. Manipulating the mouse embryo. A Laboratory Manual. Second Edition:1994;136-178 Cold Spring Harbor Press, Cold Spring Harbor.
29. Hsu S.Y., Lai R.J., Finegold M., Hsueh A.J. Targeted overexpression of Bcl-2 in ovaries of transgenic mice leads to decrease follicle apoptosis, enchanced folliculogenesis, and increased germ cell tumorigenesis. Endocrinology. 137:1996;4837-4843.
30. Kananen, K., Markkula, M., Rainio, E., Su, J.-G.J., Hsueh, A.J.W., Huhtaniemi, I.T., 1995. Gonadal tumorigenesis in transgenic mice bearing the mouse inhibin α-subunit promoter/SV 40 T-antigen fusion gene: Characterization of ovarian tumors and establishment of gonadotropin-responsive granulosa cell lines. Mol. Endocrinol. 9, 616.627.
31. Kananen K., Markkula M., El-Hefnawy T., Zhang F.-P., Paukku T., Su J.-G.J., Hsueh A.J.W., Huhtaniemi I.T. The mouse inhibin α-subunit promoter directs SV 40 T-antigen to Leydig cells of transgenic mice. Mol. Cell Endocrinol. 119:1996;135-146.
32. Kananen K., Markkula M., Mikola M., Rainio E.-M., McNeilly A., Huhtaniemi I. Gonadectomy permits the adrenocortical tumorigenesis in mice transgenic for the mouse inhibin α-subunit promoter/Simian virus 40 T-antigen fusion gene; evidence for negative autoregulation of the inhibin α-subunit gene. Mol. Endocrin. 10:1996;1667-1677.
33. Kananen Rilianawati, K., Paukku, T., Markkula, M., Rainio, E.-M., Huhtaniemi, I., 1997. Suppression of gonadotropins inhibits gonadal tumorigenesis in mice transgenic for mouse inhibin α-subunit promoter/Simian Virus 40 T-antigen fusion gene. Endocrinology 138, 3521-3531.
34. Keinan D., Madigan M.B., Bardin C.W., Chen C.-L.C. Expression and regulation of testicular inhibin α-subunit gene in vivo and in vitro. Mol. Endocrinol. 3:1989;29-35.
35. Kondoh G., Nishimune Y., Nishizawa Y., Hayasaka N., Matsumoto K., Hakura A. Establishment and further characterization of a line of transgenic mice showing testicular tumorigenesis at 100% incidence. J. Urol. 152:1994;2151-2154.
36. Krummen L.A., Moore A., Woodruff T.K., Covello R., Taylor R., Working P., Mather J. Localization of inhibin and activin binding sites in the testis during development by in situ ligand binding. Biol. Reprod. 50:1994;734-744.
37. Kwan H., Pecenka V., Tsukamato A., Parslow T.G., Guzman R., Lina T.P., Muller W.J., Leder P., Varmus H.E. Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice. Mol. Cell. Biol. 12:1992;147-154.
38. Livingston D.M., Bradley M.K. The Simian Virus 40 large T-antigen. A lot packed into a title. Mol. Biol. Med. 4:1987;63-80.
39. Majdic G., McNeilly A.S., Sharpe R.M., Evans L.R., Groome N.P., Saunders P.T. Testicular expression of inhibin and activin subunits and follistatin in the rat and human fetus and neonate and during postnatal development in the rat. Endocrinology. 138:1997;2136-2147.
40. Matzuk M.M., Finegold M.J., Hsueh A.J.W., Bradley A. Inhibin is a tumour-supressor gene with gonadal specificity in mice. Nature. 360:1992;313-319.
41. Mercer J.E. At the cutting age. Pituitary gonadotropin gene regulation. Mol. Cell. Endocrinol. 73:1990;C63-C67.
42. Meunier H., Rivier C., Evans R.M., Vale W. Gonadal and extragonadal expression of inhibin α, βA, and βB subunits in various tissues predict diverse functions. Proc. Natl. Acad. Sci. USA. 85:1988;247-251.
43. Moolten F., Wells J.M. Curability of tumors bearing herpes thymidine kinase gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 256:1990;1550-1552.
44. Nishiyama Y., Rapp F. Anticellular effects of 9-(2-hydroxymethyl) guanine against herpes simplex virus-transformed cells. J. Gen. Virol. 45:1979;227-230.
45. O'Shaughnessy P.J., Gray S.A. Gonadotropin-dependent and gonadotropin-independent development of inhibin subunit messenger ribonucleic acid levels in the mouse ovary. Endocrinology. 136:1995;2060-2065.
46. Palmiter R.D., Brinster R.L. Germ-line transformation of mice. Ann. Rev.Genet. 20:1986;465-499.
47. Paquis-Flucklinger V., Michiels J.-F., Vidal F., Alquier C., Pointis G., Bourdon V., Cuzin F., Rassoulzadegan M. Expression in transgenic mice of the large T antigen of polyoma virus induces Sertoli cell tumors and allows the establishment of different cell lines. Oncogene. 8:1993;2087-2094.
48. Peschon J.J., Behringer R.R., Cate R.L., Harwood K.A., Idzerden R.L., Brinster R.L., Palmiter R.D. Directed expression of an oncogene to Sertoli cells in transgenic mice using Müllerian inhibiting substance regulatory sequence. Mol. Endocrinol. 6:1992;1403-1411.
49. Peterson C.M., Zimniski S.J. A long-acting gonadotropin-releasing hormone agonist inhibits the growth of human ovarian epithelial carcinoma (BG-1) heterotransplanted in the nude mice. Obstet. Gynecol. 76:1990;264-267.
50. Ram Z., Culver K.W., Oshiro E.M., Viola J.J., De Vroom H.L., Otto E., Long Z., Chiang Y., McGarrity G.J., Muul L.M., Katz D., Blaese R.M., Oldfield E.H. Therapy of malignant brain tumours by intratumoral implantation of retroviral vector-producing cells. Nat. Med. 3:1997;1354-1358.
51. Rao I.M., Gadson P.F. Jr., Anderson E., Hornsby P.J., Mahesh V.B. Characterization of progesterone biosynthesis in a transformed granulosa cell line. Mol. Cell Endocrinol. 94:1993;121-128.
52. Rebois R.V. Establishment of gonadotropin-responsive murine Leydig tumor cell line. J. Cell Biol. 94:1982;70-76.
53. Risbridger G.P., Thomas T., Gurusinghe C.J., McFarlane J.R. Inhibin-related proteins in rat prostate. J. Endocr. 149:1996;93-99.
54. Risma K.A., Clay C., Nett T. M., Wagner T., Yun J., Nilson J.H. Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors. Proc. Natl. Acad. Sci. USA. 92:1995;1322-1326.
55. Rivier C., Rivier J., Vale W. Inhibin-mediated feedback control of follicle-stimulating hormone secretion in the female rat. Science. 234:1986;205-208.
56. Rivier C., Schwall R., Mason A., Burton L., Vaughan J., Vale W. Effect of recombinant inhibin on luteinizing hormone and follicle-stimulating hormone secretion in the rat. Endocrinology. 128:1991;1548-1554.
57. Saez J.M. Leydig cell: endocrine, paracrine, and autocrine regulation. Endocr. Rev. 15:1994;574-626.
58. Smyth C.D., Miro F., Whitelaw P.F., Howles C.M., Hillier S.G. Ovarian thecal/androgen synthesis is enhanced by a follicle-stimulating hormone-stimulated paracrine mechanism. Endocrinology. 133:1993;1532-1538.
59. Stalvey J.R.D., Payne A.H. Luteinizing hormone receptors and testosterone production in whole testes and purified Leydig cells from the mouse: differences among inbred strains. Endocrinology. 112:1983;1696-1701.
60. Su J.-G.J., Hsueh A.J.W. Characterization of mouse inhibin α gene and its promoter. Biochem. Biophys. Res. Commun. 186:1992;715-721.
61. Thomas H., Balkwill F.R. Oncogene transgenic mice as therapeutic models in cancer research. Eur. J. Cancer. 30:1994;533-537.
62. Tone S., Katoh Y., Fujimoto H., Togashi S., Yanazawa M., Kato Y., Higashinakagawa T. Expression of inhibin α-subunit gene during mouse gametogenesis. Differentiation. 44:1990;62-68.
63. Vanderstichele H., Delaey B., de Winter J., de Jong F., Rombauts L., Verhoeven G., Dello C., van der Voorde A., Briers T. Secretion of steroids, growth factors, and cytokines by immortalized mouse granulosa cell lines. Biol. Reprod. 50:1994;1190-1202.
64. Wang H., Ascoli M., Segaloff D. Multiple luteinizing hormone/choriogonado-tropin receptor messenger ribonucleic acid transcripts. Endocrinology. 129:1991;133-138.
65. Wimalasena J., Dostal R., Meehan D. Gonadotropins, estradiol, and growth factors regulate epithelial ovarian cancer cell growth. Gynecol. Oncol. 46:1992;345-350.
66. Windle J.J., Weiner R.I., Mellon P.L. Cell lines of the pituitary gonadotrope lineage derived by targeted oncogenesis in transgenic mice. Mol. Endocrinol. 4:1990;597-603.
67. Woodruff T.K., Lyon R.J., Hansen S.E., Rice G.C., Mather J. Inhibin and activin locally regulate rat ovarian folliculogenesis. Endocrinology. 127:1990;3196-3205.
68. 125I]rh-activin A in immature female and male rats. Endocrinology. 132:1993;725-734.
69. Xiang X., Benson K.F., Chada K. Mini-mouse: disruption of the pigmy locus in a transgenic insertional mutant. Science. 247:1990;967-969.
70. Yano T., Pinski J., Halmos G., Szepechazi K., Groot K., Schally A.V. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc. Natl. Acad. Sci. USA. 91:1994;7090-7094.